ClinicalTrials.gg
TerminatedNCT03127592FDCETCB-IIIUpdated Sep 9, 2026

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

A Phase 3 interventional study of Fixed Dose Combination and Etodolac in Pain, Acute, sponsored by Apsen Farmaceutica S.A.. Terminated at 1 site in Brazil. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Apsen Farmaceutica S.A. · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
recruitment difficulty

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Acute Pain with a site in Brazil — 1 open to participants now, 1 under way, none of them phase 3. Acute Pain · Brazil.

Enrollment
3rd of 13
140 · median 60
Started
2020
the only one that year
Phase 3
2 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
Apsen Farmaceutica S.A.

Among the 13 studies in Acute Pain with a site in Brazil, this one is the 3rd largest by enrollment, is the only one that started in 2020, is one of 2 in phase 3, and was the 7th registered.

Acute Pain

1,077 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

1 of the 13 studies in Acute Pain with a site in Brazil is open now. Recruiting first, the newest first:

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute Pain with a site in Brazil, or all of them as a file.
02

Study summary

This Phase III study will compare the efficacy and tolerability of a Fixed Dose Combination of Etodolac + Cyclobenzaprine versus the isolated drugs in postoperative pain control after impacted third molar extraction.

03

Conditions studied

  • Pain, Acute

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy research participants of both sexes (male and female non-pregnant), aged 18 years or over, underwent impacted third molar extraction surgery

Exclusion criteria

Exclusion Criteria:

  • Presence of any event and / or pathology at the site of interest that may interfere with and contraindicate the performance of the surgical procedure at the discretion of the Investigator, including periodontitis, odontogenic tumors or cysts (associated or not with the third molar), trauma, presence of Inflammation and / or infection;
  • Present or past history of any cardiac, gastrointestinal, respiratory, hepatic, renal, endocrine, neurological, metabolic, psychiatric, hematological event;
  • Previous diagnosis of alcohol and drug abuse defined by ;
  • Current or past history (for less than 12 months) of smoking;
  • Use of illicit drugs;
  • History of bleeding / bleeding or coagulation disorders, gastric ulcer and / or active peptic hemorrhage;
  • Any finding of clinical (clinical / physical), laboratory or cardiac evaluation () observation that is interpreted by the investigating physician as a risk to the participant;
  • Use of drugs that potentially interfere with the kinetics / dynamics of acetaminophen or any other medicinal product considered by the Investigator;
  • Known to the active principles used during the study (etodolac and cyclobenzaprine);
  • Women in gestation or breastfeeding, as well as women who present a positive pregnancy test (β - hCG) during the study screening / selection period;
  • Professionals directly involved in the realization of the present study and their relatives;
  • Participant of the research that has participated in clinical study protocols in the last 12 (twelve) months, unless the Investigator deems that there may be direct benefit to it.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Group 1

    1 active treatment (Fixed Dose Combination) + 2 placebos

    Drug: Fixed Dose Combination

  • Active comparator
    Group 2

    1 active treatment (Cyclobenzaprine) + 2 placebos

    Drug: Cyclobenzaprine

  • Active comparator
    Group 3

    1 active treatment (Etodolac) + 2 placebos

    Drug: Etodolac

Interventions

  • DrugFixed Dose Combination

    Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg

  • Individual drug

    Also known as: Flancox

  • Individual drug

    Also known as: Miosan

06

What researchers measure

Primary outcomes

  1. Superiority of the Fixed Dose Combination versus Isolated active substances

    The Primary outcome will be accessed by the individual response rate in relation to the pain intensity calculated by the Visual Analogic Scale (VAS) scale performed after 4 hours of administration of the first dose of medicines

    Time frame: 4 hours

Secondary outcomes

  1. Individual response rate

    Individual response rate in relation to the evaluation of pain intensity calculated through the Visual Analogic Scale (VAS) measure in times 6h, 12h, 24h, 48h and 72h

    Time frame: 6h, 12h, 24h, 48h and 72h

  2. Edema

    Absence of edema after 4 hours of drug administration and at the end of treatment

    Time frame: 4 hours

  3. Mandibula constriction

    Absence of mandibular constriction after 4 hours of drug administration and at the end of treatment

    Time frame: 4 hours

  4. Use of rescue medication

    Proportion of participants requiring the use of rescue medication over the 3 days of treatment in each treatment group

    Time frame: 3 days

07

Study locations

1 site
  • Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.
    Valinhos, São Paulo 13271-130, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Jul 2022, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2017
First posted
Apr 25, 2017
StartActual
Oct 5, 2020
Primary completionActual
Jul 26, 2022
CompletionActual
Jul 26, 2022
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03127592
Lead sponsor
Apsen Farmaceutica S.A.
Responsible party
Sponsor
First posted
Apr 25, 2017
Start date
Oct 5, 2020
Primary completion
Jul 26, 2022
Completion
Jul 26, 2022
Last update
Sep 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion